Is Piramal Enterprises a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Piramal Enterprises Ltd is a good quality company .

Is Piramal Enterprises undervalued or overvalued?

The key valuation ratios of Piramal Enterprises Ltd's currently when compared to its past seem to suggest it is in the Somewhat Undervalued zone .

What is Piramal Enterprises share price return in the past 10 years?

Piramal Enterprises Ltd share price has appreciated 3.4% annually (CAGR) over the past ten years.

Is Piramal Enterprises a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Piramal Enterprises Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

Piramal Enterprises Ltd - Stock Valuation and Financial Performance

Name: Piramal Enterprises
Brand: Piramal Enterprises

BSE: 500302 | NSE: PEL | Finance - NBFC | Small Cap

Place order

Piramal Enterprises Share Price

₹1,093.65 -28.15 -2.51%
as on 20-Dec'24 16:59

10 Year X-Ray of Piramal Enterprises:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Operating Income (₹ Cr.)	5,123	6,381	8,547	10,639	11,883	13,068	12,809	7,726	8,934	10,020	8,367
YoY Gr. Rt. %	-	24.6%	33.9%	24.5%	11.7%	10%	-2%	-39.7%	15.7%	12.2%	-
Adj EPS (₹ )	160.3	50.9	70.4	277.4	77.7	1.1	59.1	80.6	417.7	-74.9	-84.1
YoY Gr. Rt. %	-	-68.3%	38.4%	293.8%	-72%	-98.6%	5420.6%	36.4%	418.4%	-117.9%	-
BVPS (₹ )	660.1	728.3	837.1	1,438.6	1,440.7	1,355.4	1,508.2	1,487.1	1,301.5	1,179	1,194.4
YoY Gr. Rt. %	-	10.3%	14.9%	71.9%	0.1%	-5.9%	11.3%	-1.4%	-12.5%	-9.4%	-
To view Net Profit/Total Funds (%) Colour Rating Guide click here ⓘ
Net Profit/Total Funds (%)	10.6	3	2.5	7.6	2.1	-0.7	1.8	1.8	10.2	-1.9	0

CAGR ⓘ

CAGR Colour Code Guide ⓘ


	9 Years	5 Years	3 Years	1 Years
Net Interest Income	7.7%	-3.4%	-7.9%	12.2%
Adj EPS	-191.9%	-199.3%	-208.3%	-117.9%
BVPS	6.7%	-3.9%	-7.9%	-9.4%
Share Price	3.4%	-7.3%	-24.6%	24%

Key Financial Ratios


RATIOS \ YEARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Asset Quality Ratio	To view Asset Quality Ratio Colour Rating Guide click here ⓘ
Net NPA to Net Advances (%)	0	0	0	0	0	0	0	0	0	0	-
Capitalization Ratio	To view Capitalization Ratio Colour Rating Guide click here ⓘ
Capital Adequacy Ratio (%)	0	0	0	0	0	0	0	0	0	0	-
Margins
Net Profit Margin (%)	52.5	14.2	12.7	45.5	14.2	-4.2	11	21.5	111.6	-16.8	-22.7
Performance Ratios	To view Performance Ratios Colour Rating Guide click here ⓘ
Return on Equity (%)	25.6	7.3	7.8	23.4	6.3	-1.9	4.4	4.8	30	-5.9	-7

Recent Performance Summary

No data to display

Return on Equity is Poor

Total Income has declined -5.43 CAGR in last 3 years

Net Profit has declined -208.26 CAGR in last 3 years

Total income growth is poor in last 4 quarters

Latest Financials - Piramal Enterprises Ltd.

	Standalone	Consolidated
TTM EPS (₹)	10.6	-84.1
TTM Sales (₹ Cr.)	2,126	8,367
BVPS (₹.) ⓘ	965.3	1,194.4
Reserves (₹ Cr.) ⓘ	21,818	26,885
P/BV ⓘ	1.13	0.92
PE ⓘ	103.71	0.00

From the Market
52 Week Low / High (₹)	736.60 / 1275.40
All Time Low / High (₹)	16.56 / 3224.09
Market Cap (₹ Cr.)	24,659
Equity (₹ Cr.)	45.1
Face Value (₹)	2
Industry PE ⓘ	28.2

Management X-Ray of Piramal Enterprises:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Piramal Enterprises

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Piramal Enterprises

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Total Income (Cr.)

ROE (%)

BVPS (Rs.)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Income	5,377	6,827	8,781	10,903	12,516	14,058	13,511	8,592	10,483	11,066
Interest Income	5,123	6,381	8,547	10,639	11,883	13,068	12,809	7,726	8,934	10,020
Other Income ⓘ	255	446	234	264	634	990	702	866	1,549	1,045
Expenditure ⓘ	5,038	5,919	7,460	8,940	9,522	12,651	10,115	6,370	12,559	12,257
Interest Expense ⓘ	511	959	2,031	2,978	4,100	5,321	4,209	4,282	4,041	4,400
Operating Expenses ⓘ	4,372	4,690	5,165	5,575	4,872	5,256	5,666	1,063	1,914	3,302
Provisions	156	270	265	387	549	2,075	240	1,025	6,604	4,555
Exceptional Items ⓘ	2,696	46	-10	0	-452	0	59	-153	7,976	-2,087
Profit Before Tax ⓘ	3,035	954	1,310	1,964	2,542	1,407	3,456	2,068	5,900	-3,278
Taxes ⓘ	345	50	228	-2,876	852	1,960	2,043	406	-4,068	-1,595
Profit After Tax	2,690	905	1,082	4,840	1,690	-553	1,413	1,662	9,969	-1,684
Adjusted EPS (₹)	160.3	50.9	70.4	277.4	77.7	1.1	59.1	80.6	417.7	-74.9
Dividend Payout Ratio (%)	12%	33%	29%	9%	35%	1,314%	56%	41%	7%	-13%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Equity Capital	11,736	12,948	14,883	26,562	27,220	30,572	34,018	35,489	31,059	26,557
Share Capital ⓘ	35	35	35	36	37	45	45	48	48	45
Reserves ⓘ	11,701	12,914	14,848	26,526	27,183	30,526	33,973	35,441	31,011	26,512
Minority Interest	29	0	13	12	9	0	1121	1348	0	0
Long Term Borrowings	7,817	11,760	18,776	25,355	29,033	24,454	34,163	58,713	48,958	48,628
Current Liabilities	5,694	10,542	18,962	22,479	31,213	23,673	13,873	11,249	9,520	11,767
Trade Payables	510	703	764	874	961	990	1,178	1,697	399	295
Short term borrowings	2,829	6,829	12,079	14,666	15,578	7,950	3,362	3,122	4,504	7,469
Other Liabilities	-3,339	-7,531	-12,844	-15,540	-16,535	-8,940	-4,541	-4,819	-4,903	-7,763
Total Liabilities ⓘ	25,276	35,250	52,634	74,409	87,480	78,699	83,175	1,06,799	89,537	86,952
Assets
Non Current Asset	19,912	30,595	43,471	61,843	75,089	62,586	62,782	42,031	32,733	22,316
Loan Asset	0	0	0	0	0	0	0	0	0	0
Other Non Current Asset ⓘ	19,912	30,595	43,471	61,843	75,089	62,586	62,782	42,031	32,733	22,316
Current Asset	5,364	4,655	9,163	12,566	12,390	16,113	20,393	64,768	56,804	64,637
Current Investment	947	634	3,464	5,199	2,448	2,950	3,562	1,972	179	231
Other Current Asset	4,417	4,021	5,699	7,367	9,943	13,163	16,831	62,796	56,625	64,406
Total Assets ⓘ	25,276	35,250	52,634	74,409	87,480	78,699	83,175	1,06,799	89,537	86,952

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	-2,207	-6,956	-10,057	-15,967	-11,611	7,516	3,665	8,443	1,378	26
Cash Flow From Investing Activity ⓘ	6,177	-604	-2,403	-1,768	-827	7,469	-2,772	-2,131	-407	-1,872
Cash Flow From Financing Activity ⓘ	-3,865	7,544	13,570	18,650	10,752	-13,019	2,072	-6,774	-3,287	1,390
Net Cash Flow ⓘ	106	-16	1,111	916	-1,686	1,966	2,964	-462	-2,316	-455

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Operational & Financial Ratios
EPS (₹)	165	52	73	284	80	1	59	81	418	-75
DPS (₹)	20	18	21	25	28	14	33	33	31	10
BVPS (₹)	680	750	863	1474	1476	1355	1508	1487	1301	1179
Performance Ratios
ROA (%)	10.6	3.0	2.5	7.6	2.1	-0.7	1.8	1.8	10.2	-1.9
ROE (%)	25.6	7.3	7.8	23.4	6.3	-1.9	4.4	4.8	30.0	-5.9
ROCE (%)	18.7	7.9	9.0	8.5	8.6	8.6	10.5	7.7	11.6	1.4
Valuation Parameters
Price/Book(x)	1.3	1.4	2.2	1.7	1.9	0.7	1.2	1.5	0.5	0.7

Piramal Enterprises Ltd Stock News

Piramal Enterprises Ltd FAQs

What is the share price of Piramal Enterprises?

Company share prices are keep on changing according to the market conditions. The closing price of Piramal Enterprises on 20-Dec-2024 16:59 is ₹1,093.7.

What is the market cap of Piramal Enterprises?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 20-Dec-2024 16:59 the market cap of Piramal Enterprises stood at ₹24,659.4.

What is the P/E ratio of Piramal Enterprises?

The latest P/E ratio of Piramal Enterprises as of 20-Dec-2024 16:59 is 103.7.

What is the P/B ratio of Piramal Enterprises?

The latest P/B ratio of Piramal Enterprises as of 20-Dec-2024 16:59 is 1.13.

What is the 52-week high and low of Piramal Enterprises?

The 52-week high of Piramal Enterprises is ₹1,275.4 and the 52-week low is ₹736.6.

What is the TTM revenue of Piramal Enterprises?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Piramal Enterprises is ₹2,126 ( Cr.) .

About Piramal Enterprises Ltd

Piramal Enterprises Limited (PEL) is one of India’s leading diversified companies, with a presence in Financial Services and Pharmaceuticals. Driven by both organic as well as inorganic strategy, PEL has steered dynamic business growth over the three decades of its existence.

PEL made its foray into the financial services sector with Piramal Capital & Housing Finance Limited (PCHFL), a housing finance company registered with the National Housing Bank (NHB) that is engaged in various financial services businesses. It provides end-to-end financing solutions in both wholesale and retail funding opportunities across sectors such as real estate and infrastructure, renewable energy, hospitality, logistics, industrials, auto components etc. Through its group companies, the platform has strategic partnerships with leading global pension funds such as Canadian Pension Plan Investment Board (CPPIB), APG and Ivanhoe Cambridge.

Products and services offered by the company

Piramal Pharma

Pharma Solutions
Critical Care
Consumer Products
PhytoMedicine

Financial Services

Piramal Capital & Housing Finance
India Resurgence Fund (IndiaRF)

Awards & Recognitions

For Financial Services

Piramal Capital & Housing Finance Limited was awarded Best Overall Investment Manager for Real Estate in India at the 15th Annual Euromoney Real Estate Survey 2019 - September 2019.
Piramal Capital & Housing Finance Limited won ?Best Private Equity Deal of the Year at the 11th Estate Awards by Franchise India - August 2019.
Piramal Capital & Housing Finance Limited was awarded ?Best In-House Legal Team of the Year in the Banking and Financial Services sector at the Asian Legal Business India Law Awards 2020 - March 2020.

For Pharma

Piramal Pharma Solutions was honoured with the ?Frost & Sullivan Global Customer Service Leadership Award - June 2019.
Piramal Pharma Solutions was ranked 1st by Biospectrum India in Bio Services - October 2019.
Piramal Pharma Solutions won the ?2020 Manufacturing Supply Chain Operational Industry Excellence Award within the Pharmaceuticals Category at the 9th Edition of Manufacturing Supply Chain Awards - March 2020.

Milestones

1980: In the early 1980s a young Ajay Piramal takes the reins of the Piramal Group.
1984: Acquired Gujarat Glass
1988: Acquired Nicholas Laboratories.
1990: Gujarat Glass is merged with the group company, Nicholas Piramal India Ltd
1991: A new formulation plant at Pithampur in Madhya Pradesh is commissioned.
1992: Set up a second formulation plant at Pithampur in Madhya Pradesh with state-of-the-art manufacturing facilities.
1992: Nicholas Laboratories Ltd. renamed to Nicholas Piramal India, Ltd.
1993: Piramal entered into a joint venture agreement with Allergan of U.S.A., the leading manufacturers of Ophthalmic products.
1994: A joint venture agreement was entered into with Satelec, France for dental care products.
1995: The bulk drug division of Sumitra Pharmaceutical and Chemicals Ltd. Hyderabad transferred to NPIL.
1996: Entered into a product tie-up with F. Hoffman-La-Roche.
1996: Boehringer Mannheim is acquired.
1997: NPIL entered into an agreement with Reckitt & Colman for joint marketing of the latter's OTC products in India.
1998: Acquired the research unit of Hoechst Marion Roussel (India) in Mumbai.
1998: Nicholas Piramal India Ltd (NPIL) forges joint venture with Boots Healthcare International (BHI) to develop and market consumer healthcare products in India.
2000: Rhone Poulenc India Limited is acquired.
2000: Started collaborative research with Centre for Biochemical Technology in the field of gene technology.
2000: Research alliance established with Hindustan Lever for developing Cosmoceuticals and personal care products.
2002: ICI Pharma is acquired.
2003: Global Bulk Drugs is acquired.
2004: Nicholas forges alliance with scientists from Imperial College of the UK to carry out research in the field of rheumatoid arthritis.
2005: Avecia Pharmaceutical is acquired.
2006: Pfizer's Morpeth UK facility acquired.
2007: Scientists from Piramal led the first exploration by an Indian pharmaceutical company to develop drug leads from geographies like Antarctica.
2008: Khandelwal Laboratories is acquired.
2009: RxEliteinc, the U.S. based inhalation anesthetic gas distribution business, is acquired.
2010: Biosyntech, Inc., Canada is acquired by Piramal Enterprises Ltd., part of the Life Sciences vertical, Bio-Orthopedics division.
2010: Piramal sells the diagnostics division to Super Religare Laboratories Ltd.
2010: Acquisition of iPill, an oral contraceptive brand, from Cipla.
2011: Bharat Serum and Vaccines Ltd - Anaesthetics business buyout by Piramal Enterprises Ltd.
2011: Piramal Realty acquires Mafatlal Mills in Byculla, Mumbai.
2011: Piramal Healthcare acquires 11% of Vodafone India.
2011: UN Conference on Trade and Development’s World Investment Report 2011 ranks Piramal Healthcare as No. 5 in the top 10 pharmaceutical contract manufacturers worldwide.
2011: Piramal Healthcare acquires Indiareit, a real estate focused investment trust with AUM of $760 million.
2011: Fortune 500 ranks Piramal Healthcare in the top-50 largest corporations across India.
2011: Piramal's Pharma Solutions manufacturing site at Grangemouth, Scotland becomes the world’s first contract supplier at commercial scale for ADCs.
2011: Piramal Healthcare acquires Indiareit, a real estate focused investment trust with AUM of $760 million.
2012: Piramal Realty wins the auction of the landmark Hindustan Unilever training centre at Worli Sea Face, Mumbai.
2012: Decision Resources Group acquires Abacus International, a UK based global market access solutions company for many of the world’s leading health care companies.
2012: BST-CarGel, company’s innovative bio-orthopedic product for cartilage repair, receives European CE mark approval.
2012: Piramal Enterprises starts a Non-Banking Financial Company (NBFC) focused on lending to real estate, education and hospitals
2012: Piramal Enterprises acquires health care information management firm, Decision Resources Group, USA for US$635 million
2012: Piramal Realty, a privately owned real estate entity, was formed
2012: Piramal Healthcare Limited is renamed to Piramal Enterprises Limited.
2013: Piramal Enterprises Limited acquires Molecular Imaging Development portfolio of Bayer Pharma
2013: Imaging division's lead radiopharmaceutical, Florbetaben, accepted for review by the US FDA and EMA for the visual detection of Beta-Amyloid in Alzheimer's disease
2013: Piramal Water (Sarvajal) honoured with 'Enabling Technology Award of the Year 2013' by Frost & Sullivan
2013: Piramal Enterprises Ltd. consumer products' division acquires the brand CALADRYL® in India.
2014: APG Asset Management, the Dutch pension fund asset manager and Piramal Enterprises Limited announce a strategic alliance for investing in rupee denominated mezzanine instruments issued by infrastructure companies in India with a target investment of US$1 billion, over the next 3 years
2014: Piramal Enterprises Limited acquires 9.99% equity stake in Shriram City Union Finance Limited
2014: Piramal Enterprises Limited agrees to acquire an effective 20% equity stake in Shriram Capital Limited, a financial services company, for an aggregate consideration of INR 20.14 Billion
2014: Canada Pension Plan Investment Board (CPPIB) and Piramal Enterprises Limited announce a US$500 million Strategic Alliance for Residential Development Debt Financing in India; appoint Piramal Fund Management (at the time known as Indiareit) as advisor
2015: Piramal Enterprises Ltd. acquires Kentucky based Specialty Pharmaceutical CDMO, Coldstream Laboratories Inc.
2015: DRG has acquired Healthcare Business Insights (HBI), a trusted provider of best Practice research, training and services to more than 1,400 hospitals across the U.S.
2015: Warburg Pincus to invest Rs 1800 crore in Piramal Realty.
2015: Piramal Realty secures $150 million (Rs 900 crore) from Goldman Sachs.
2015: Piramal Realty launches a new community for natural and holistic living at Balkum, Thane, Mumbai: Piramal Vaikunth
2015: Piramal Enterprises acquires the Baby Care brand – Little’s for the Consumer Products Business
2016: Piramal Enterprises announces the sale of its Canada-based cartilage repair product, BST-CarGel® to Smith & Nephew
2016: Piramal Realty launches its signature project, Piramal Aranya in Byculla, Mumbai
2016: Piramal Enterprises enters an agreement to acquire four brands from Pfizer Limited for its Consumer Products Business
2016: Piramal Realty forays into commercial real estate with the launch of Piramal Agastya Corporate Park in Kurla, Mumbai
2016: Piramal Enterprises enters into an agreement to acquire Ash Stevens Inc., a US based Contract and Drug Manufacturing Organisation (CDMO) for High Potency APIs (HPAPIs)
2016: Piramal Enterprises Limited and Bain Capital Credit to pursue distressed debt investing in India
2016: Piramal Enterprises Critical Care Division expands its product portfolio; enters into an agreement to acquire Janssen's Injectable Anaesthesia and Pain Management products
2016: Piramal Enterprises Critical Care Division expands its product portfolio; enters into an agreement to acquire Janssen's Injectable Anaesthesia and Pain Management products
2016: Piramal Fund Management launches an Innovative Flexi Lease Rental Discounting (LRD) for Commercial Assets.
2017: Piramal Enterprises Limited announces its plan to enter Housing Finance
2017: Piramal Enterprises Limited and Ivanhoé Cambridge announce Partnership to Invest in Residential Developments in India
2017: Piramal Realty marks exclusive pre-Launch of Piramal Revanta
2017: Piramal Enterprises Completes the Acquisition of a Portfolio of Drugs for Spasticity and Pain Management from Mallinckrodt LLC.
2018: Piramal Finance Limited Forays into the Hospitality Sector
2018: Piramal Realty launches Piramal Mahalaxmi, its Flagship Project in South Mumbai
2018: NITI Aayog Partners with Piramal Foundation to Transform 25 Aspirational Districts across 7 states in India, in the areas of Health & Nutrition and Education.
2018: IndiaRF Announces $156 million Investment in Archean Group’s Marine Chemicals Business.
2019: Piramal Enterprises Limited signed a Memorandum of Understanding with Canada Pension Plan Investment Board (CPPIB) to set-up Asset Aggregation Platform focused on renewables.
2019: Supreme Court Exempts Saridon from the List of Banned FDCs.
2019: Piramal Swasthya has been recognized by USAID with the ‘Inclusive Health Access Award’ for its High Impact Healthcare Platform
2019: Piramal Foundation and Gates Foundation Partner to Setup a Tribal Health Collaborative for India
2019: Piramal Swasthya and The Rockefeller Foundation Announce Partnership to Accelerate India’s Public Health Transformation
2019: Piramal Divests its DRG Business for $950 million.
2019: PEL raises funds of Rs 14,500 crore in FY2020.
2019: Piramal Realty Makes a Foray into Value Housing Segment
2020: Piramal Group Commits INR 25 Crores to COVID-19 Relief Effort.
2020: Carlyle and Piramal Pharma Sign Agreement on 20% Strategic Growth Investment.